GlobeNewswire Inc.··NaOKYO Pharma CDO Backs Pipeline With $49K Share Purchase as Phase 2b/3 Trial Looms
OKYO Pharma's Chief Development Officer purchases 30,980 shares at $1.59, signaling confidence in urcosimod as company prepares Phase 2b/3 trial launch in H1 2026.
OKYOclinical-stage biopharmaceuticalneuropathic corneal pain